Prebiotic XOS Reshapes Gut Microbiome and Slows Aging in Mouse Models

Aging is increasingly understood as a process deeply intertwined with gut microbiome health. Dysbiosis — imbalance in gut bacterial communities — is associated with chronic inflammation, cognitive decline, and oxidative stress, all hallmarks of biological aging. Dietary prebiotics that selectively feed beneficial bacteria offer a non-pharmacological avenue to address these mechanisms.

This study focused on xylo-oligosaccharide (XOS), a prebiotic derived from plant cell walls, and investigated how it interacts with gut microbiota at a fine-grained level. Researchers conducted in vitro fermentation experiments using healthy human fecal samples, then applied microbiome sequencing, functional genomic analysis, and metabolomics to characterize bacterial responses and downstream metabolic changes.

XOS significantly altered gut microbiota composition, enriching taxa including Blautia, Bifidobacterium longum subsp. longum, and Faecalibacterium prausnitzii. Genomic analysis confirmed that these XOS-responsive bacteria possessed varied capacities to utilize XOS, correlating with the degree to which their abundance increased. Metabolomics revealed meaningful shifts in GABA, serotonin, and inosine — metabolites with roles in neurological function, immune modulation, and inflammation. Network analyses identified three distinct microbial-metabolite interaction clusters, suggesting layered mechanisms of XOS degradation and response.

The findings were validated in a D-galactose-induced aging mouse model, where XOS supplementation improved cognitive performance, reduced inflammatory markers, and lowered oxidative stress — a strong translational signal for anti-aging applications.

While promising, the study relies on in vitro fermentation and an accelerated aging mouse model, neither of which perfectly replicates human aging. Clinical trials in older human populations will be essential to confirm these effects and determine optimal XOS dosing.